Trial reportBone marrow transplantation2005
Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning.
Trial report in Bone marrow transplantation, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 56 citations in OpenAlex.
- Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD.Bone marrow transplantation · 2009Trial
- Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies.Bone marrow transplantation · 2008Trial
- Feasibility and results of bone marrow transplantation from an HLA-mismatched unrelated donor for children and young adults with acquired severe aplastic anemia.International journal of hematology · 2007Trial
- High Overall and GVHD-Free Survival in Patients with Aplastic Anemia ReceivingBlood cell therapy · 2020Article
- Update of humanized animal disease models in studying Graft-versus-host disease.Human vaccines & immunotherapeutics · 2018Article
- Hematopoietic stem cell transplantation in FANCJ/BRIP1 fanconi anemia.Bone marrow transplantation · 2017Article
- Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia.International journal of hematology · 2013Review
- Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18-40 years without an HLA-identical sibling and failing immunosuppression.Bone marrow transplantation · 2013Review
- Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors.Haematologica · 2010Article
- Is it time for a change? The case for early application of unrelated allo-SCT for severe aplastic anemia.Bone marrow transplantation · 2010Review
- Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anemia.Bone marrow transplantation · 2010Article
- Implications of CD34+ cell dose on clinical and haematological outcome of allo-SCT for acquired aplastic anaemia.Bone marrow transplantation · 2010Article
- Myelodysplasia and acute leukemia as late complications of marrow failure: future prospects for leukemia prevention.Hematology/oncology clinics of North America · 2009Review
- Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia.Bone marrow transplantation · 2008Article
- Marked improvement of cardiac function early after non-myeloablative BMT in a heavily transfused patient with severe aplastic anemia and heart failure.Bone marrow transplantation · 2007Article
- Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia.Bone marrow transplantation · 2007Article
- Marrow transplantation for severe aplastic anemia with significant renal impairment.Bone marrow transplantation · 2007Article
- Review
- Graft failure and severe autoimmune haemolysis following fludarabine-based reduced-intensity matched unrelated donor bone marrow transplantation for severe aplastic anaemia: salvage by second transplant with conventional dose conditioning.Bone marrow transplantation · 2006Article
- Outcome of bone marrow transplantation in acquired and inherited aplastic anaemia in the Republic of Ireland.Irish journal of medical scienceArticle
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft failure, regimen-related toxicity and graft-versus-host disease (GVHD) are the critical barriers to unrelated donor transplants for aplastic anaemia (AA). We investigated the use of a novel conditioning regimen consisting of alemtuzumab (humanized CD52 antibody), fludarabine and cyclophosphamide in seven patients with AA, who underwent bone marrow transplant procedure using matched unrelated donors. The aetiology of AA was acquired (n=3), Fanconi's (n=3) and congenital (n=1). Median age was 13 years (range 8-35). All the donors were fully matched for HLA class I and II antigens using high-resolution typing. All the patients engrafted at a median of 18 days (range 13-35). Two patients died of transplant-related complications: one of adenovirus disease and the other developed extensive chronic GVHD of skin followed by cytomegalovirus (CMV) disease. Three patients developed Grade II acute GVHD disease (GVHD); none had Grade III-IV acute GVHD. Of the six evaluable patients, only one developed chronic GVHD. We conclude that this conditioning regimen for unrelated donor transplants for AA is sufficiently immunosuppressive to allow stable engraftment and appears to have a favourable impact on the incidence and severity of GVHD, warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.